Literature DB >> 17185442

Treating low-risk febrile neutropenia: Jenny's story.

R Phillips1, R Skinner, J C Chisholm.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17185442      PMCID: PMC2083145          DOI: 10.1136/adc.2006.095521

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  17 in total

1.  Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.

Authors:  A S Petrilli; L S Dantas; M C Campos; C Tanaka; V C Ginani; A Seber
Journal:  Med Pediatr Oncol       Date:  2000-02

2.  Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer.

Authors:  Gerardo Quezada; Theresa Sunderland; Ka Wah Chan; Kenneth Rolston; Craig A Mullen
Journal:  Pediatr Blood Cancer       Date:  2007-03       Impact factor: 3.167

3.  Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.

Authors:  C A Mullen; D Petropoulos; W M Roberts; M Rytting; T Zipf; K W Chan; S J Culbert; M Danielson; S S Jeha; J F Kuttesch; K V Rolston
Journal:  Cancer       Date:  1999-07-01       Impact factor: 6.860

4.  A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  I Hann; C Viscoli; M Paesmans; H Gaya; M Glauser
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

5.  "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia.

Authors:  R J Klaassen; T R Goodman; B Pham; J J Doyle
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

6.  Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.

Authors:  Claudi Oude Nijhuis; Willem A Kamps; Simon M G Daenen; Jourik A Gietema; Winette T A van der Graaf; Harrie J M Groen; Edo Vellenga; Els M Ten Vergert; Karin M Vermeulen; Hillie G de Vries-Hospers; Eveline S J M de Bont
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

7.  Out-patient management of febrile neutropenia in indigent paediatric patients.

Authors:  I A Malik
Journal:  Ann Acad Med Singapore       Date:  1997-11       Impact factor: 2.473

Review 8.  Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.

Authors:  Liat Vidal; Mical Paul; Itsik Ben dor; Karla Soares-Weiser; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2004-06-16       Impact factor: 5.790

9.  Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.

Authors:  J A Talcott; R D Siegel; R Finberg; L Goldman
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

10.  Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.

Authors:  Hugo Paganini; Sandra Gómez; Silvina Ruvinsky; Pedro Zubizarreta; Antonio Latella; Lidia Fraquelli; Alejandro Santillán Iturres; Lidia Casimir; Roberto Debbag
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

View more
  3 in total

1.  Febrile neutropenia: transition towards a risk-directed approach.

Authors:  P Anoop; M A Anjay
Journal:  Arch Dis Child       Date:  2007-05       Impact factor: 3.791

2.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Ottavio Ziino; Fabio Tucci; Mario Renato Rossi
Journal:  Pediatr Rep       Date:  2011-02-24

Review 3.  Febrile neutropenia in children with cancer.

Authors:  Stéphane Paulus; Simon Dobson
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.